The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $87.51

Today's change-1.78 -1.99%
Updated February 24 4:00 PM EST. Delayed by at least 15 minutes.
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $87.51

Today's change-1.78 -1.99%
Updated February 24 4:00 PM EST. Delayed by at least 15 minutes.

Biomarin Pharmaceutical Inc crosses below 200-day moving average

Biomarin Pharmaceutical Inc closed sharply lower Friday, dropping (U.S.)$1.78 or 1.99% to (U.S.)$87.51 and crossing below its 200-day moving average. Shares have lost 2.63% over the last five days, but have gained 5.64% over the last year to date. This security has underperformed the S&P 500 by 8.04% during the last year.

Key company metrics

  • Open(U.S.) $87.99
  • Previous close(U.S.) $89.29
  • High(U.S.) $88.82
  • Low(U.S.) $85.88
  • Bid / Ask(U.S.) $85.01 / (U.S.) $87.50
  • YTD % change+5.64%
  • Volume2,390,386
  • Average volume (10-day)1,146,006
  • Average volume (1-month)1,094,685
  • Average volume (3-month)1,225,020
  • 52-week range(U.S.) $72.96 to (U.S.) $102.49
  • Beta1.57
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$3.72
Updated February 24 4:00 PM EST. Delayed by at least 15 minutes.

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue300280300237
Total other revenue--------
Total revenue300280300237
Gross profit236229249194
Total cost of revenue64515243
Total operating expense390340873318
Selling / general / administrative14312011098
Research & development175161167159
Depreciation / amortization--888
Interest expense (income), net operating--------
Unusual expense (income)005990
Other operating expenses, total72-623
Operating income-90-60-573-81
Interest income (expense), net non-operating-10-10-10-10
Gain (loss) on sale of assets--------
Other--------
Income before tax-92-67-583-89
Income after tax-91-43-424-85
Income tax, total-1-24-159-4
Net income-91-43-424-85
Total adjustments to net income--------
Net income before extra. items-91-43-424-85
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-91-43-424-85
Inc. avail. to common incl. extra. items-91-43-424-85
Diluted net income-91-43-424-85
Dilution adjustment--------
Diluted weighted average shares172168163162
Diluted EPS excluding extraordinary itemsvalue per share-0.53-0.26-2.61-0.53
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.53-0.26-0.21-0.53